Novel antineoplastic compound containing pyrimidine skeleton and hedgehog pathway antagonist activity

A hedgehog pathway and antagonist technology, applied in the field of medicine, can solve the problems of tumor metastasis and regeneration with little effect, achieve the effect of blocking tumor cell metastasis and regeneration, and inhibiting abnormal growth of cells

Active Publication Date: 2014-04-02
SUZHOU KINTOR PHARMA
View PDF2 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] Metastasis and regeneration are the characteristics of malignant tumors, and they are also difficult problems in the treatment of malignant tumors. Even the new generation of targeted drugs have little effect on tumor metastasis and regeneration

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel antineoplastic compound containing pyrimidine skeleton and hedgehog pathway antagonist activity
  • Novel antineoplastic compound containing pyrimidine skeleton and hedgehog pathway antagonist activity
  • Novel antineoplastic compound containing pyrimidine skeleton and hedgehog pathway antagonist activity

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0063] This example provides a novel anti-tumor compound A1, the synthesis method of which is as follows:

[0064]

[0065] 1) Synthesis of intermediate A1-2:

[0066] Dissolve 4-tert-butoxycarbonylpiperidone (10g, 50.2mmol) in 40ml of N,N-dimethylformamide, and add N,N-dimethylformamide dimethyl acetal (6g , 50mmol), after addition, react at 80°C for 12 hours. Cooled to room temperature, added to ethyl acetate (150mL) and water (50mL), the organic phase was washed twice with saturated brine (50mL), dried and filtered over anhydrous sodium sulfate, and rotary evaporated to obtain an orange crude product (13g). Vote for the next response.

[0067] 2) Synthesis of intermediate A1-3:

[0068] At room temperature, dissolve hemimethylthiourea sulfate (6.98g, 25.1mmol) and sodium ethoxide (3.28g, 40mmol) in 40ml of ethanol, stir for half an hour, then add the intermediate A1-2 (13g, 50.2 mmol) of ethanol solution in 10 ml, reflux for 12 h, cool to room temperature, distill un...

Embodiment 2

[0081] This embodiment provides a novel antitumor compound A2, the synthesis method of which is as follows:

[0082]

[0083] 1) Synthesis of intermediate A2-1:

[0084] A1-4 (1g, 3.19mmol) and ethylamine aqueous solution (71%, 1mL) were successively dissolved in ethanol (10mL) under stirring, heated to reflux, after 12 hours, cooled to room temperature, decompressed to remove the solvent, and concentrated The product was purified by column chromatography (mobile phase: petroleum ether:ethyl acetate=4:1) to obtain a white solid (400mg, 45%).

[0085] 2) Synthesis of intermediate A2-2:

[0086] Dissolve A2-1 (400mg, 1.44mmol) in a small amount of dichloromethane, add hydrogen chloride in saturated ethyl acetate solution (3mL), stir at room temperature for 3 hours, spin off the solvent under reduced pressure, and add the concentrate to saturated aqueous sodium bicarbonate solution (5mL) and dichloromethane (20mL), the organic phase was washed with saturated brine (10mL), dr...

Embodiment 3

[0091] This embodiment provides a novel antitumor compound A3, the synthesis method of which is as follows:

[0092]

[0093] 1) Synthesis of intermediate A3-1:

[0094] A1-4 (1g, 3.19mmol) and cyclopropylamine (300mg, 5.26mmol) were successively dissolved in ethanol (10mL) under stirring, heated to reflux, after 12 hours, cooled to room temperature, decompressed to spin off the solvent, and concentrate After purification by column chromatography (mobile phase: petroleum ether: ethyl acetate = 4:1), a white solid (460mg, 50%) was obtained.

[0095] 2) Synthesis of intermediate A3-2:

[0096] Dissolve A3-1 (460 mg, 1.58 mmol) in a small amount of dichloromethane, add hydrogen chloride in saturated ethyl acetate solution (3 mL), stir at room temperature for 3 hours, spin off the solvent under reduced pressure, and add the concentrate to saturated aqueous sodium bicarbonate solution (5 mL) and dichloromethane (20 mL), the organic phase was washed with saturated brine (10 mL)...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a novel antineoplastic compound containing pyrimidine skeleton and hedgehog pathway antagonist activity, which comprises compound and pharmaceutically acceptable salt thereof, various isotopes, various isomers or various crystal structures, and the product comprises the structure shown in the general formula I: wherein, X is a five-membered or six-membered aromatic ring, heteroaromatic ring and heterocyclic ring, and substituted derivatives thereof. The novel antineoplastic compound containing pyrimidine skeleton and hedgehog pathway antagonist activity provided by the invention can block transmembrane protein acceptor SMO, and block hedgehog pathway Hedgehog, thereby inhibiting abnormal growth of cells, blocking migration and regeneration of tumor cells with obvious antineoplastic effect.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to a novel antitumor compound with a pyrimidine skeleton having hedgehog pathway antagonist activity. Background technique [0002] Malignant tumors are one of the most important diseases that endanger human health. There are about 10.9 million new cases of malignant tumors in the world every year, and about 6.7 million patients die of malignant tumors every year [1]. The research and development of anti-tumor drugs has undergone tremendous changes after years of research and exploration; the anti-tumor drugs commonly used in clinical treatment in the past are mainly cytotoxic drugs, which have poor selectivity, strong toxic and side effects, and are easy to treat. In recent years, with the rapid development of life science research, the signal transduction in malignant tumor cells, the regulation of cell cycle, the induction of apoptosis, angiogenesis and the interaction between c...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07D471/04C07D487/04A61K31/519A61K31/444A61K31/53A61K31/4985A61K31/506A61K31/55A61K31/5025A61K31/5377A61P35/00A61P35/02
CPCC07D471/04C07D487/04
Inventor 张小虎
Owner SUZHOU KINTOR PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap